Transaction DateRecipientSharesTypePriceValue
22nd May 2020Lisa N Colleran1,165Open or private purchase$17.83$20,774.86
13th May 2020Mezerville Roberto De10Open or private purchase$17.13$171.30
8th October 2019Asset Management, Llc Jw1,000Open or private purchase$18.74$18,740.00
19th September 2019Asset Management, Llc Jw1,000Open or private purchase$20.00$20,000.00
4th September 2019Lisa N Colleran535Open or private purchase$19.13$10,234.55
23rd August 2019Asset Management, Llc Jw1,000Open or private purchase$20.40$20,400.00
20th August 2019Asset Management, Llc Jw1,000Open or private purchase$20.00$20,000.00
19th August 2019Nicholas Sheridan Lewin2,700Open or private purchase$20.11$54,288.63
16th August 2019Asset Management, Llc Jw2,000Open or private purchase$21.42$42,840.00
12th August 2019Asset Management, Llc Jw3,000Open or private purchase$22.15$66,450.00
Establishment Labs Holdings
Establishment Labs Holdings logo

Establishment Labs Holdings, Inc. engages in the design, development, manufacture, and marketing of silicone breast implants. The company was founded by Juan Jose Chacon-Quiros in 2013.

Ticker: ESTA
Sector: Health Technology
Industry: Medical Specialties
SEC Central Index Key (CIK): 1688757
Employees: 602
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Inventory, Net: $29 M (0%)
Assets, Current: $136 M (42%)
Property, Plant and Equipment, Net: $16 M (0%)
Other Assets, Noncurrent: $360 Th (-2%)
Assets: $157 M (34%)
Accounts Payable, Current: $8 M (-19%)
Accrued Liabilities, Current: $11 M (0%)
Liabilities, Current: $21 M (-11%)
Long-term Debt, Excluding Current Maturities: $49 M (1%)
Other Liabilities, Noncurrent: $2 M (0%)
Liabilities: $75 M (-2%)
Common Stock, Value, Issued: $212 M (43%)
Common Stock, Shares, Issued: $24 M (0%)
Retained Earnings (Accumulated Deficit): $155 M (22%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $4 M (439%)
Treasury Stock, Value: $29 Th (0%)
Treasury Stock, Shares: $4 M (0%)
Stockholders' Equity (Parent): $82 M (0%)
Liabilities and Equity: $157 M (34%)
Revenue: $10 M (0%)
Gross Margin: $7 M (-68%)
Research and Development: $2 M (-63%)
Operating Income/Loss: $10 M (-44%)
Provision for income taxes: $194 Th (-54%)